CT Features of Epidermal Growth Factor Receptor–Mutated Adenocarcinoma of the Lung: Comparison with Nonmutated Adenocarcinoma
Authors:
- 1 June 2016
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 11 (6) , 819-826
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Correlation of EGFR mutation and predominant histologic subtype according to the new lung adenocarcinoma classification in Chinese patientsMedical Oncology, 2013
- Validation of the IASLC/ATS/ERS Lung Adenocarcinoma Classification for Prognosis and Association with EGFR and KRAS Gene Mutations: Analysis of 440 Japanese PatientsJournal of Thoracic Oncology, 2013
- Imaging Characteristics of Stage I Non-Small Cell Lung Cancer on CT and FDG-PET: Relationship with Epidermal Growth Factor Receptor Protein Expression Status and SurvivalKorean Journal of Radiology, 2013
- Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinomaCancer, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Epidermal growth factor receptor gene mutations in atypical adenomatous hyperplasias of the lungLaboratory Investigation, 2007
- A review of the benefit–risk profile of gefitinib in Asian patients with advanced non‐small‐cell lung cancerCurrent Medical Research and Opinion, 2006
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004